Ney Carter Borges: Simplifying Blood Pressure Control After Intracerebral Hemorrhage
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Craig S Anderson et al., published in NEJM, adding:
“Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
Survivors of spontaneous intracerebral hemorrhage (ICH) remain at exceptionally high risk of recurrent stroke, with long-term blood pressure control representing the only proven preventive strategy. However, therapeutic inertia, poor adherence, and treatment complexity frequently prevent patients from reaching recommended blood pressure targets.
The multinational TRIDENT trial evaluated whether a fixed-dose, low-dose triple antihypertensive pill (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg), added to standard care, could improve secondary prevention after ICH.
In this double-blind, placebo-controlled study, 1,670 clinically stable patients with previous spontaneous ICH were randomized after a successful run-in phase and followed for a median of 2.5 years.
The triple-pill strategy achieved substantially better blood pressure control, maintaining a mean systolic blood pressure of 127 mmHg compared with 138 mmHg in the placebo group.
This translated into a 39% relative reduction in recurrent stroke (HR 0.61; 95% CI, 0.41–0.92), largely driven by a marked reduction in recurrent intracerebral hemorrhage (HR 0.40).
Major cardiovascular events were also significantly reduced (HR 0.67), while cardiovascular mortality remained similar between groups.
Approximately 35 patients needed to be treated to prevent one recurrent stroke, highlighting a clinically meaningful benefit.
Although treatment discontinuation was more frequent in the intervention group, primarily because of protocol-mandated increases in serum creatinine or symptomatic hypotension, serious adverse events were not increased, and no evidence suggested accelerated long-term kidney disease progression.
The TRIDENT trial provides compelling evidence that early implementation of a simplified fixed-dose combination can substantially improve blood pressure control and reduce recurrent cerebrovascular events after ICH.
Beyond demonstrating efficacy, this strategy addresses one of the greatest barriers in hypertension management-medication adherence-offering a practical, scalable approach that may reshape future secondary stroke prevention guidelines for this particularly vulnerable population.”
Title: Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
Authors: Craig S Anderson, Clara K Chow, H Asita de Silva, Bimsara Senanayake, Kolawole Wahab, Rustam Al-Shahi Salman, Catharina J M Klijn, Sheila Ouriques Martins, Natalie Espinosa, Lauren Kuhles, Laurent Billot, Hisatomi Arima, Cheryl Carcel, Xia Wang, Qiang Li, Sana Shan, Mathangi Shanthakumar, Huy Thang Nguyen, Dilum Palliyaguruge, Janaka Peiris, Udaya K Ranawaka, Senaka Bandusena, Thambipillai Rajendiran, Darshana Wijegunasinghe, Harsha Gunasekera, Indunil Wijeweera, Athula Dissanayake, Ajantha Keshavaraj, Reginald O Obiako, Rufus Akinyemi, Luiz Nasi, Rodrigo Bazan, Carla Heloisa Cabral Moro, Mariana Battaglini, Viviane Zétola, Wan Chung Law, Yuen Kang Chia, Dennis Cordato, Rohan Grimley, Anuradha Dahanayaka, Sonali Liyanagamage, Nilukshi Fernando, Nihara Abdul Rasheed, Nodar Kakabadze, Maia Beridze, Mythily Aravinthan, Vithoosan Sahathevan, Devasmitha Wijesundara, Pramith Ruwanpathirana, Wan Asyraf Wan Zaidi, Tinatin Kherkheulidze, Urs Fischer, Ana Cláudia de Souza, Tsong-Hai Lee, Christopher Chen, Octavio Pontes-Neto, Thompson Robinson, Jiguang Wang, Sharon L Naismith, Michael Barnett, Carlos Delfino, Shoujiang You, Feifeng Liu, Candice Delcourt, Tom J Moullaali, Tim Wilkinson, Neil Watson, Karla Santo, Qiao Han, Mariana Almudi Souza, Wilmar M T Jolink, Anderson Berni Cristofari, Zien Zhou, Floris H Schreuder, Richard I Lindley, Manuela Armenis, Mark Woodward, Ruth Freed, Lili Song, John Chalmers, Anthony Rodgers

Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026